215 Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes.
http://www.nature.com/nature/journal/v514/n7521/full/nature13564.html
214 Artificial sweeteners induce glucose intolerance by altering the gut microbiota.
http://www.nature.com/nature/journal/v514/n7521/full/nature13793.html
213 The α2A-adrenergic receptor antagonist yohimbine improves insulin secretion in type 2 diabetics carrying the ADRA2A risk variant.
http://stm.sciencemag.org/content/6/257/257ra139.abstract
212 Obesity and aging result in elevated levels of central TGF-β, resulting in hypothalamic inflammation and the development of type 2 diabetes.
http://www.nature.com/nm/journal/v20/n9/abs/nm.3616.html
211 Global genomic and transcriptomic analysis of human pancreatic islets reveals novel genes influencing glucose metabolism.
http://www.pnas.org/content/111/38/13924.abstract
210 Systemic autophagy insufficiency compromises adaptation to metabolic stress and facilitates progression from obesity to diabetes.
http://www.nature.com/ncomms/2014/140926/ncomms5934/full/ncomms5934.html
209 Macrophage-inducible C-type lectin underlies obesity-induced adipose tissue fibrosis.
http://www.nature.com/ncomms/2014/140919/ncomms5982/full/ncomms5982.html
208 Pharmacological fibroblast growth factor 1 (FGF1) normalizes blood glucose in diabetic mice by means of an FGF receptor signalling pathway that is independent of its mitogenic activity.
http://www.nature.com/nature/journal/v513/n7518/full/nature13540.html
207 Reversible changes in pancreatic islet structure and function produced by elevated blood glucose.
http://www.nature.com/ncomms/2014/140822/ncomms5639/full/ncomms5639.html
206 MicroRNA-378 controls classical brown fat expansion to counteract obesity.
http://www.nature.com/ncomms/2014/140822/ncomms5725/full/ncomms5725.html
|
